skip to the content

Clinical Trials

Acute Myeloid Leukemia Study

COG #AAML0531: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

Protocol ID

06.10.088

Protocol Description

The goals of this study are:
1. To see if adding a new drug, called gemtuzumab to the current standard treatment for acute myeloid leukemia (AML) will improve the cure rate without causing more serious side effects
2. To compare the outcomes of children who have higher risk disease and receive a stem cell transplant to children who don’t have higher risk disease
3. To evaluate how well children with Down syndrome (who are over 4 years old) do when they receive the standard chemotherapy without gemtuzumab
4. To understand the biology of AML better with optional biology tests

Eligibility Criteria

Children and adolescents diagnosed with acute myeloid leukemia (AML)

Primary Investigator(s)

  • Arlene Redner, MD

Contact Information

Christine Grabowski, CCRP
(718) 470-3401
grabowsk@lij.edu

Last Update

March 29, 2010
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top
top